TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease.·~* HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry will not be sufficient for entry.·~* At least one measurable lesion as defined by the RECIST.~* Prior hormonal therapy for metastatic disease is allowed.~* Maximum of one prior chemotherapy regimen or trastuzumab-containing regimen for unresectable, locally recurrent or metastatic disease~* Prior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease.~Exclusion Criteria:~* No prior therapy with capecitabine or oxaliplatin in any setting~* No prior therapy with other platinum compounds·~* No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to beginning protocol therapy.·~* No prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.·~* No prior fluoropyrimidine therapy for metastatic disease is allowed.~* Prior adjuvant fluoropyrimidine therapy is allowed if completed \> 12 months from study entry.·~* No symptomatic brain metastasis. ·~* No evidence of serious concomitant systemic disorders incompatible with the study ·~* No peripheral neuropathy ·~* No major surgery within 28 days prior to beginning protocol therapy.·~* Negative pregnancy test·~* No current breastfeeding·~* No malabsorption syndrome·~* No evidence of serious concomitant systemic disorders incompatible with the study·~* Patients must not be treated with any of the following while on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 16 years of above at the time of screening~* ability and willingness to provide written informed consent (or to obtain consent from parent guardian where applicable) and to comply with the schedule of protocol requirements~* Diagnosis of SLE according to ACR criteria. At least 4 criteria must have been present for the diagnosis of SLE. The 4 criteria do not have to be present at the time of screening~* Active lupus nephritis defined as follows: Biopsy proven (within 16 weeks prior to screening) ISN Class III or IV (A or A/C) not include III(C) IV(C) and VI (\>90% chronic irreversible scarring)~* Relapse or resistant to (3 consecutive doses) IVCY~* Resistant lupus or Relapse lupus nephritis defined as follows:~  * Increase in serum creatinine \>/= 0.3 mg/dl or~ * Increase in proteinuria \> 1.5 g/day (which must have improved by ≥ 50% in the preceding 3 months)~* Life-time cumulative dose of IVCY \> 6 grams~* Female patients of childbearing potential must have a negative serum pregnancy~Exclusion Criteria:~Relates to SLE~* Diagnosis of rapid progressive glomerulonephritis (RPGN): doubling serum creatinine and/or crescentic glomeruli ≥ 30%~* Severe renal impairment as defined by calculated creatinine clearance or MDRD-GFR \< 30 ml/min(except creatinine clearance or MDRD-GFR \> 50 ml/min in the 12 weeks prior to screening)~* History of serious disease or complication in any organ system that not appropriate to treatment immunosuppressive drug groups.~* Severe extra-renal organ involvement~Related to Treatment~* Previous of any Mycophenolate groups in the 6 months prior to screening~* Treatment with any investigational drugs in the 3 months prior to screening~Related to General Health~* Pregnancy or breast feeding mothers.~* Concomitant condition which has required treatment moderate to high dose steroid in the 12 weeks prior to screening.~* Evidence of significant uncontrolled concomitant disease in any organ system not related to SLE.~* History of cancer, including solid tumors, hematological malignancies and carcinoma.~* Evidence of current abuse of drugs or alcohol.~Related to Laboratory Findings~* Neutrophile \< 1,500/mm3, Hb \< 7g/L, Platelet \< 50,000/mm3 (except active SLE)~* Positive HBsAg or anti-HCV or anti-HIV.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral mycophenolate sodium 1440 mg per day for 12 months
- 2 (Type: ACTIVE_COMPARATOR): Intravenous cyclophosphamide monthly for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, term infant from a singleton birth (=\>37 weeks gestational age); formula fed; primary caregiver able to read and write in English; current colicky behaviour~Exclusion Criteria:~* Infants with known genetic syndromes; birth weight (\<2500g); use of proton pump inhibitors; use of antibiotics in previous week; use of nutritional colic remedies; use of probiotics; maternal medical history of diabetes (excluding gestational diabetes), tuberculosis, or any perinatal infection while pregnant with child enrolled in study; presence of blood in infant stool sample; possible cow milk protein allergy

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: f

Study Arms:
- Experimental Infant Formula (Type: ACTIVE_COMPARATOR): Milk-based infant formula with prebiotics
- Reference group (Type: PLACEBO_COMPARATOR): Milk-based infant formula without prebiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxygen Therapy in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 years old.~* Diagnosis and clinic of chronic heart failure with ventricular dysfunction with left ventricular ejection fraction (LVEF) \<40% under optimal medical treatment regardless of its etiology and having presented at least one episode of decompensation (visits to the emergency room, hospitalizations and/or need for intravenous depletive treatment) during the last year.~* Nocturnal desaturation defined as mean SatO2 \<90% and/or Cummulative time (TC) \<90\>22 minutes to nocturnal pulse oximetry done at home.~* Signed informed consent~Exclusion Criteria:~* Chronic lung disease (includes chronic obstructive pulmonary disease with Pulmonary respiratory function (PRF) (forced expiratory volume at one second/forced vital capacity (FEV1/FVC) \<70%), diffuse interstitial diseases, pulmonary hypertension of respiratory).~* Obstructive sleep apnea-hypopnea syndrome (OSAHS) with Apnea hypopnea index (AHI) \> 14.9.~* Previous treatment with oxygen therapy.~* Not agreeing to attend periodic cardiology visits.~* Being part of other clinical studies that contraindicate an intervention.~* Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxygen Therapy (Type: ACTIVE_COMPARATOR): Participants received nocturnal oxygen therapy (minimum 6 hours) for 6 months.
- No Oxygen Therapy (Type: NO_INTERVENTION): Participants will not received oxygen therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Af Ablation In Brady-Tachy Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* paroxystic AF~* symptomatic pauses (\>5s at night or 3s during daytime)~Exclusion Criteria:~* permanent AF~* age \> 80 y~* pregnant women~* minors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AF ablation + pacemaker
- 2 (Type: ACTIVE_COMPARATOR): Pacemaker

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA III-IV~* QRS \> 120 msec~* On medical therapy, but beta blocker dose not @ target (carvedilol 25 bid, metoprolol succinate 200 qd)~Exclusion Criteria:~* QRS \< 120 msec~* On target beta blocker dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): CRT and b-blocker uptitration to target dose
- 2 (Type: ACTIVE_COMPARATOR): CRT and continuation of entry b-blocker dose to 6 month evaluation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-45 years old;~2. pathologically diagnosed with AEH for the first time;~3. desire to preserve their fertility;~4. no signs of suspicious myometrial invasion or extrauterine metastasis by enhanced magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal ultrasonography (TVUS);~5. no contraindication for metformin, megestrol acetate or pregnancy;~6. no hormone or metformin treatment within 6 months before entering the trial;~7. not pregnant when participating in the trial;~8. willing to follow the trial arrangement after being fully informed of all the risks and inconveniences caused by the trial.~Exclusion Criteria:~Patients who had one or more of the following conditions:~1. allergy history or contraindications for megestrol acetate or metformin;~2. pregnant when initiating the study;~3. alcoholism, severe infection, severe chronical diseases (dysfunction of heart, liver, lung or kidney);~4. high risk of thrombosis;~5. recurrent AEH;~6. endometrial cancer;~7. other malignancy history.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Metformin plus megestrol acetate (Type: EXPERIMENTAL): Metformin 1500mg per day plus megestrol acetate 160mg per day.
- Megestrol acetate (Type: ACTIVE_COMPARATOR): Megestrol acetate 160mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient at least 18 years of age and of any race or ethnicity who is undergoing Descemet stripping only for Fuchs dystrophy~* Is able and willing to administer eye drops~* Is able to comprehend and has signed the Informed Consent form.~Exclusion Criteria:~* Active intraocular inflammation~* Corneal ulceration, keratitis, or conjunctivitis~* Known sensitivity to any of the ingredients in the study medications~* Abnormal eyelid function~* History of herpetic keratitis~* History of non-compliance with using prescribed medication~* Current or planned pregnancy within the study duration~* Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study~* Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil (Type: EXPERIMENTAL): Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
- Placebo (Type: PLACEBO_COMPARATOR): Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Reduce Adhesions Following a Primary Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females 12 years and older undergoing a scheduled primary cesarean section at or after 24 weeks estimated gestational period~Exclusion Criteria:~* Patients transferred from outlying hospitals who expect to undergo repeat C-section at that hospital.~* Patients who have had previous laparotomy~* Patients having a previous laparoscopy demonstrating adhesions of bladder peritoneum or uterine serosa or myometrium to the parietal peritoneum or omentum or bowel to the uterus or parietal peritoneum; or involving pelvic adhesiolysis, enterolysis or other surgery on bowel located in the pelvis, uterine myomectomy , adnexectomy or other adnexal surgery including ovarian cystectomy, tuboplasty, tubal reanastomosis, and removal of endometriosis~* Patients with an adhesion score \> 0 at the time of primary cesarean section~* Patents with chorioamnionitis, appendicitis or infection of other pelvic viscera at the time of primary cesarean section.~* Patients who have taken systemic corticosteroids within 2 weeks of the primary cesarean section. Provided however, patients who have been treated with systemic betamethasone or dexamethasone to promote fetal lung maturity are not excluded~* Patients undergoing tubal sterilization at the time of the primary cesarean section~* Patients with known allergy to hyaluronic acid~* The following criteria are seen as complications or adverse events experienced by the patients in the interval after the puerperium and will therefore exclude patients:~  1. Patient who have had a pelvic inflammatory disease documented by either cervical motion, uterine or adnexal tenderness; and either oral temperature \> 101 degrees or mucopurulent cervical discharge or cervical culture positive for C. trachomatis or N. Gonorrhoeae~ 2. Patients who have pelvic abscess or diverticulitis

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: ACTIVE_COMPARATOR): Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
- Control Group (Type: NO_INTERVENTION): This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reliability and Reproducibility of the Eye Check Tonometer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or older,~* Any glaucoma patient or glaucoma suspect patient~* Presents for an appointment wearing their own soft contact lens.~Exclusion Criteria:~* Arthritis affecting the upper extremity in the patient or caregiver~* Patient unwilling or assessed to be unable to comply with the study protocol~* Any corneal abnormalities such as opacities, scars, Fuchs dystrophy, map dot fingerprint dystrophy, history of recurrent corneal abrasion, corneal surgery such as Lasik, PRK, DSAEK, transplant or implant~* History of any ongoing ocular symptoms such as eye pain or redness or discharge~* History of recent ocular surgery (done in the past 3 months)~* History of a any filtering or tube surgery for glaucoma (to reduce risk of infection associated complications)~* Recent eye infection (within the past 3 months)~* History of diabetes for \> 5 years duration~* Monocular patient~* Best corrected visual acuity\< 20/70~* Head or hand tremors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EyeCheck (Type: EXPERIMENTAL): EyeCheck pressures will be measured with contact lens in place
- Traditional Tonometer (Goldmann and Tonopen) (Type: ACTIVE_COMPARATOR): Pressures will be measured with both Goldmann and Tonopen (both traditional tonometers to take the intraocular pressure (IOP) measurements of the eye).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women\>18 years,~* during first stage of normal labor,~* at 36 to 42 weeks,~* with epidural analgesia and informed signed consent~Exclusion Criteria:~* Cesarean section delivery,~* clotting disorders,~* prostaglandin allergy,~* absent consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Misoprostol (Type: EXPERIMENTAL): 10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two misoprostol tablets taken orally (400µg) following cord clamp
- PLACEBO (Type: PLACEBO_COMPARATOR): 10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two placebo tablets taken orally following cord clamp.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~INCLUSION CRITERIA FOR PATIENTS:~* Having a diagnosis of advanced lung cancer or malignant brain tumor for two to six months~* Receiving on-going care from the medical oncologist at the Seidman Cancer Center~* Having a primary and distance caregiver involved in their care, support, and/or care planning~* English as a primary language~* Capacity to provide informed consent, as validated by the oncologist~INCLUSION CRITERIA FOR DISTANCE CAREGIVERS:~* Family caregiver of a patient with advanced lung cancer or malignant brain tumor~* Patient and distance caregiver perception that this caregiver's geographic location is such that precludes routine participation in medical appointments~* English as primary language~* Capable of providing informed consent~* Computer ownership with internet access~Exclusion Criteria:~EXCLUSION CRITERIA FOR PATIENTS:~* No primary caregiver~* Enrolled in hospice~EXCLUSION CRITERIA FOR DISTANCE CAREGIVERS:~* Those who routinely participate in most of the patient's medical appointments (once or more per month)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm I (usual care) (Type: ACTIVE_COMPARATOR): Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer
- Arm II (usual care with CLOSER intervention) (Type: EXPERIMENTAL): Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues